rheumatoid arthritis

Galapagos CEO talks next steps as coronavirus stalls the biotech's top drug
Galapagos CEO talks next steps as coronavirus stalls the biotech's top drug
BioPharma Dive
Galapagos
Gilead Sciences
filgotinib
rheumatoid arthritis
FDA
COVID-19
Flag link:
Gilead gets ball rolling on JAKs game in Japan
Gilead gets ball rolling on JAKs game in Japan
Endpoints
Gilead Sciences
Japan
filgotinib
Eisai
rheumatoid arthritis
Flag link:
As promised, Gilead and Galapagos file filgotinib to FDA and get a speedy review
As promised, Gilead and Galapagos file filgotinib to FDA and get a speedy review
Fierce Biotech
Gilead Sciences
FDA
filgotinib
Galapagos
rheumatoid arthritis
Flag link:
Amgen snags another Enbrel outcomes-based payment deal as it seeks to prop up aging blockbuster
Amgen snags another Enbrel outcomes-based payment deal as it seeks to prop up aging blockbuster
Fierce Pharma
Amgen
Enbrel
Abarca
PBMs
rheumatoid arthritis
Flag link:
ICER says ‘marginal’ benefits for AbbVie’s new RA drug
ICER says ‘marginal’ benefits for AbbVie’s new RA drug
Pharmaforum
ICER
AbbVie
Rinvoq
rheumatoid arthritis
biosimilars
Flag link:
ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class
ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class
Fierce Pharma
ICER
AbbVie
Rinvoq
rheumatoid arthritis
JAK inhibitors
Flag link:
Gilead, Galapagos share 52-week update on filgotinib
Gilead, Galapagos share 52-week update on filgotinib
Fierce Biotech
Gilead Sciences
Galapagos
filgotinib
clinical trials
rheumatoid arthritis
Flag link:
ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach
ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach
Fierce Pharma
ICER
JAK inhibitors
rheumatoid arthritis
AbbVie
Rinvoq
Pfizer
Xeljanz
Incyte
olumiant
Flag link:
Rheumatoid Arthritis Drug May Help Repair Heart After Heart Attacks
Rheumatoid Arthritis Drug May Help Repair Heart After Heart Attacks
BioSpace
VentriGel
Ventrix
rheumatoid arthritis
heart attacks
Flag link:
Price, safety will test blockbuster billing for AbbVie's new arthritis drug
Price, safety will test blockbuster billing for AbbVie's new arthritis drug
Biopharma Dive
AbbVie
rheumatoid arthritis
drug pricing
Rinvoq
Flag link:
Rinvoq approval bolsters AbbVie's autoimmune portfolio
Rinvoq approval bolsters AbbVie's autoimmune portfolio
BioCentury
AbbVie
FDA
Rinvoq
Upadacitinib
rheumatoid arthritis
Flag link:
AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib
AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib
Fierce Pharma
AbbVie
Humira
biosimilars
Europe
psoriasis
rheumatoid arthritis
Skyrizi
Flag link:
GSK begins phase 3 trial for otilimab in patients with rheumatoid arthritis
GSK begins phase 3 trial for otilimab in patients with rheumatoid arthritis
Pharmaceutical Business Review
GSK
clinical trials
rheumatoid arthritis
otilimab
monoclonal antibodies
Flag link:
Watch out AbbVie: Gilead is fast on your heels at the FDA with rival JAK inhibitor filgotinib
Watch out AbbVie: Gilead is fast on your heels at the FDA with rival JAK inhibitor filgotinib
Endpoints
Gilead Sciences
AbbVie
FDA
JAK inhibitors
filgotinib
Upadacitinib
rheumatoid arthritis
Flag link:
3 Drugs Under FDA Review With Blockbuster Potential
3 Drugs Under FDA Review With Blockbuster Potential
Motley Fool
AbbVie
Upadacitinib
rheumatoid arthritis
Novartis
brolucizumab
wet age-related macular degeneration
Celgene
ozanimod
relapsing multiple sclerosis
Flag link:
Pfizer announces results from XELJANZ XR ORAL Shift study
Pfizer announces results from XELJANZ XR ORAL Shift study
Pharmaceutical Business Review
Pfizer
Xeljanz
clinical trials
rheumatoid arthritis
Flag link:
Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose
Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose
Fierce Pharma
Eli Lilly
Incyte
olumiant
safety data
Humira
rheumatoid arthritis
Flag link:
4 Blockbuster Drug Launches to Watch in 2019
4 Blockbuster Drug Launches to Watch in 2019
Motley Fool
drug launches
AbbVie
Alexion Pharmaceuticals
Aimmune Therapeutics
Skyrizi
psoriasis
Upadacitinib
rheumatoid arthritis
Ultomiris
PNH
AR101
peanut allergy
Flag link:
EMA sounds its own safety alarm for Pfizer blockbuster, but they’re also not forcing a limit on dosing — yet
EMA sounds its own safety alarm for Pfizer blockbuster, but they’re also not forcing a limit on dosing — yet
Endpoints
Pfizer
Xeljanz
Europe
EMA
rheumatoid arthritis
Flag link:
2 Biotech Stocks With Major Incoming Catalysts
2 Biotech Stocks With Major Incoming Catalysts
Yahoo/Motley Fool
Axsome Therapeutics
AXS-05
depression
Galapagos
filgotinib
Gilead Sciences
rheumatoid arthritis
Flag link:

Pages